Navigation Links
Cytochroma Closes $45 Million Series C Financing
Date:7/30/2008

Proceeds to Advance Clinical Development Of Lead Drug Candidates

MARKHAM, ON, July 30 /PRNewswire/ - Cytochroma today announced the closing of a CDN $45 million Series C financing. The financing was led by a new investor, Mitsubishi Tanabe Pharma Corporation ("MTPC"), and supported by a number of existing investors including Vengrowth Advanced Life Sciences Fund Inc., Caisse de Depot et Placement du Quebec, Novo A/S, Canadian Medical Discoveries Fund Inc., T(2)C(2)/Bio 2000 Limited Partnership, GrowthWorks Canadian Fund Ltd., BDC Capital Inc., and VentureLink Brighter Future Fund Inc.

Charles W. Bishop, PhD, Cytochroma's President and CEO stated, "We are grateful for the strong support of MTPC and our existing investors as we work to achieve our goal of becoming an integrated specialty pharmaceutical company. This latest funding provides Cytochroma with the financial capability to aggressively drive the development of our clinical-stage therapeutic pipeline."

The new funding will be used to advance Cytochroma's portfolio of vitamin D-based therapeutics into mid- and late-stage clinical trials. Cytochroma's product candidates target disorders related to altered vitamin D metabolism in chronic kidney disease ("CKD") patients, and include CTA018 and CTAP201 for the treatment of secondary hyperparathyroidism ("SHPT"), and CTAP101 for the treatment of vitamin D insufficiency. These three lead products address significant markets that are expected to grow to more than $1.4 billion annually by 2013 in North America.

In connection with the financing, Seiichi Kiso, PhD, MBA, General Manager, Business Development & Licensing Department of MTPC, and Joseph Regan, GrowthWork's Vice President, Investments, have joined Cytochroma's Board of Directors bringing the number of directors to six. Elizabeth Douville, PhD, Vice President of GeneChem Management Inc., has retired from the Board after more than nine years of service with the Company.

Alan Lewis, Ph.D., Chairman of Cytochroma's Board of Directors, commented, "I would like to thank Elizabeth for her guidance in helping to bring Cytochroma to this important point in its development. I am also pleased to welcome Seiichi Kiso and Joe Regan to our Board and look forward to benefiting from their experience and expertise, as we continue to build a strong CKD-focused specialty pharmaceutical company."

Dr. Kiso joined Tanabe Seiyaku Co., Ltd. in 1982, where he served in managerial positions across Product Development, R&D Planning, and Corporate Development & Licensing. He has been General Manager, Business Development & Licensing Department, at MTPC since October 2007. Dr. Kiso received his MSc from Kyoto Pharmaceutical University, an MBA from Kobe University, and a PhD from Nagoya University School of Medicine.

Mr. Regan joined GrowthWorks in early 2003, and brings 15 years of life sciences venture capital and pharmaceutical industry experience. He has been active in both company creation and the strategic growth of portfolio companies. Mr. Regan has an Honours BSc from the University of Guelph and an MBA from McMaster University.

About Chronic Kidney Disease

According to the National Kidney Foundation, more than eight million patients in the U.S. suffer from moderate CKD (Stages 3 and 4) to severe CKD (Stage 5). Stages 3 and 4 CKD are characterized by progressively decreasing kidney function as measured by glomerular filtration rate. In Stage 5, kidney function is altogether absent and patients require regular dialysis or kidney transplant for survival. An estimated 70-90% of CKD patients have vitamin D insufficiency, which can lead to SHPT and resultant debilitating bone diseases. Mounting evidence continues to link vitamin D insufficiency with progression of CKD and death. CKD is caused most frequently by diabetes or hypertension, both of which are consequences of a growing obesity epidemic in countries worldwide.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and SHPT associated with CKD. The Company's vitamin D-based therapeutics are designed to safely and effectively treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in these same patients. For more information, please visit http://www.cytochroma.com.


'/>"/>
SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma Appoints R. Richard Wieland II As CFO
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
4. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
5. AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury
6. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
7. MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
8. Raptor Pharmaceuticals Closes $10 Million Private Placement
9. China Pharma Holdings, Inc. Closes $10 Million Financing
10. Transdel Pharmaceuticals Closes $4 Million Financing
11. Dilon Technologies Closes First Quarter With Record Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to announce Doug ... Doug began his career at PBI-Gordon in February 1988, after finishing his masters in ... roles, ranging from customer service to national product manager, to helping develop, name and ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs ... on May 31st and June 1st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/3/2016)... , May 3, 2016  Dr. Thomas P. ... in The Woodlands, Texas , now ... percent of treated fat cells in just 25-minutes, leaving ... to 90 percent of Americans report feeling bothered by ... fat reduction procedures are a growing industry. This innovative ...
(Date:5/2/2016)... Sunnyvale, CA (PRWEB) , ... May 02, 2016 , ... ... visualization solutions today announced the addition of three Secure Remote Desktop modules to its ... the remote desktops from Linux and Unix servers to the user’s PC over encrypted ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):